Tafluprost-AFP-168-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETafluprostCat. No.: HY-B0600CAS No.: 209860-87-7Synonyms: AFP-168; MK2452分式: CHFO分量: 452.53作靶點(diǎn): Others作通路: Others儲存式: Pure form -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 16.5 mg/mL (36.46 mM; Nee

2、d ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.2098 mL 11.0490 mL 22.0980 mL5 mM 0.4420 mL 2.2098 mL 4.4196 mL10 mM 0.2210 mL 1.1049 mL 2.2098 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Tafluprost(AFP-168)是抗青光眼前列腺素（PG）類似物。REFERENCES1. Kuwayama

3、, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension:1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEshort-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.2. Kumagami, T., et al., Comparison of corneal safety and intraocula

4、r pressure-lowering effect of tafluprost ophthalmic solution with otherprostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5.3. Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. ClinOphthalmol, 2013. 7: p. 1411-6.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax: